CJC-1295 (without DAC) and Testosterone Interaction

Monitor
Mechanism-based 51% confidence

CJC-1295 (without DAC) and Testosterone have an interaction requiring monitoring for interaction with 51% confidence. Both CJC-1295 (without DAC) and Testosterone can elevate estrogen. Combined estrogenic load increases risk of gynecomastia, water retention, and mood changes. Monitor estradiol levels and consider AI if needed. These compounds primarily affect different organ systems.

Compound Profiles

CJC-1295 (without DAC)

Short-Acting Growth Hormone Releasing Hormone Analog

Binds GHRH receptors on somatotroph cells in the pituitary gland, stimulating cAMP production and physiological GH pulses. The brief 30-minute half-life allows pulsatile release versus prolonged elevation.

Half-life: 30 minutes - 2 hours Typical dose: 100-300mcg per injection growth hormone, weight loss
ghrh receptor carcinogenic riskestrogenicinsulin disruptingteratogenic
View full profile

Testosterone

Anabolic-Androgenic Steroid | Primary Male Sex Hormone

Testosterone exerts its effects primarily through binding to the intracellular androgen receptor (AR), forming a hormone-receptor complex that translocates to the nucleus and modulates gene transcription. This drives protein synthesis in skeletal muscle (anabolic effect), stimulates erythropoietin production in the kidneys to increase red blood cell mass, promotes osteoblast activity and bone mineral density, and regulates libido and cognitive function.

Half-life: ~8 days (cypionate) Typical dose: 100-200 mg/week (TRT) anabolic, sexual health, metabolic
5 alpha reductaseandrogen receptoraromataseepo receptor androgeniccarcinogenic riskestrogenichematocrit raising
View full profile

Combined Organ Load

Gonads
moderate
Heart
low
GI Tract
low
Pituitary
low
Liver
low
Pancreas
low

Shared Safety Flags

2x 2 compounds share the carcinogenic-risk safety flag (CJC-1295 (without DAC), Testosterone). Monitor accordingly.
2x 2 estrogenic compounds (CJC-1295 (without DAC), Testosterone). Combined estrogen elevation — monitor E2 and consider aromatase inhibitor.
2x 2 compounds share the teratogenic safety flag (CJC-1295 (without DAC), Testosterone). Monitor accordingly.

Frequently Asked Questions

Can I take CJC-1295 (without DAC) with Testosterone?

Yes, but with caution. Both CJC-1295 (without DAC) and Testosterone can elevate estrogen. Combined estrogenic load increases risk of gynecomastia, water retention, and mood changes. Monitor estradiol levels and consider AI if needed. Regular monitoring is advised.

Is CJC-1295 (without DAC) and Testosterone safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: carcinogenic risk, estrogenic, teratogenic. Monitor accordingly.

What are the interactions between CJC-1295 (without DAC) and Testosterone?

Both CJC-1295 (without DAC) and Testosterone can elevate estrogen. Combined estrogenic load increases risk of gynecomastia, water retention, and mood changes. Monitor estradiol levels and consider AI if needed. This assessment has 51% confidence and is inferred from pharmacological mechanism analysis.

How should I time CJC-1295 (without DAC) and Testosterone?

CJC-1295 (without DAC) has a half-life of 30 minutes - 2 hours and Testosterone has a half-life of ~8 days (cypionate). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: CJC-1295 (without DAC) vs Testosterone

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.